At the European Society for Medical Oncology (ESMO) Asia 2015 Congress, held in Singapore from 18 December to 21 December 2015, Atsushi Ohtsu, MD, PhD, from National Cancer Center, Kashiwa, Japan, reviews promising approaches for the treatment of patients with gastrointestinal cancer, including molecular targeted therapies and clinical studies of anti-PD-1 antibodies, such as pembrolizumab, for advanced gastric or gastroesophageal junction adenocarcinoma.
Roles of targeted therapy and immunotherapy for gastrointestinal cancer
5th February 2016
Oncology
Please rate the quality of this content
We are sorry that this content was not interesting for you!
Let us improve this content!
Tell us how we can improve this content?